Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone

Anne L Langston, Marion K Campbell, William D Fraser, Graeme S MacLennan, Peter L Selby, Stuart H Ralston, PRISM Trial Group

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Bisphosphonates are widely regarded as the treatment of choice for Paget's disease of bone (PDB) because of their potent inhibitory effects on bone turnover, but the effects of bisphosphonate therapy on symptoms and complications of PDB have been little studied. Here we report the results of a randomized trial that compared the effects of symptomatic treatment with intensive bisphosphonate therapy in a cohort of 1324 patients with PDB who were followed up for a median of 3 years (range 2 to 5 years). The symptomatic treatment group was treated only if they had pagetic bone pain, for which they were first given analgesics or anti-inflammatory drugs, followed by bisphosphonates if they did not respond. The intensive group received repeat courses of bisphosphonates irrespective of symptoms with the aim of reducing and maintaining serum alkaline phosphatase (ALP) levels within the normal range. The endpoints were fracture, orthopedic surgery, quality of life, bone pain, and hearing thresholds. Serum ALP levels were significantly lower in the intensive treatment group than in with the symptomatic treatment group within 4 months of commencing treatment and remained lower throughout the study (p < .001). There was no difference between the groups in quality of life (as assessed by the SF36 questionnaire), in overall bodily pain, or in pagetic bone pain. Hearing thresholds, as assessed by audiometry did not change significantly and did not differ between the treatment groups. Clinical fractures occurred in 46 of 661 patients (7.0%) in the intensive treatment group compared with 49 of 663 patients (7.4%) in the symptomatic treatment group, and orthopedic surgery was required in 50 of 661 patients (7.3%) in the intensive treatment group and in 55 of 663 patients (8.3%) in the symptomatic treatment group. These differences were not significant. Subgroup analyses of patients with elevated ALP levels at baseline and those who did or did not receive bisphosphonates during the study yielded similar results to those in the study group as a whole. We conclude that striving to maintain normal ALP levels with intensive bisphosphonate therapy confers no clinical advantage over symptom-driven management in patients with established PDB. Neither management strategy had a significant beneficial impact on pain or quality of life (Clinical trial registration number ISRCTN12989577). (C) 2010 American Society for Bone and Mineral Research.

Original languageEnglish
Pages (from-to)20-31
Number of pages12
JournalJournal of Bone and Mineral Research
Volume25
Issue number1
Early online date18 Dec 2009
DOIs
Publication statusPublished - Jan 2010

Keywords

  • clinical trial
  • paget's disease of bone
  • bisphosphonate
  • fracture
  • quality-of-life
  • double-blind
  • disodium etidronate
  • zoledronic acid
  • postmenopausal osteoperosis
  • osteitis deformans
  • single infusion
  • natural-history
  • fracture risk
  • risedronate

Cite this